ZERIA PHARMACEUTICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,044 JPY | +0.34% |
|
+5.42% | +1.34% |
| Sales 2024 | 75.72B 485M | Sales 2025 * | 79.9B 511M | Capitalization | 89.79B 575M |
|---|---|---|---|---|---|
| Net income 2024 | 7.73B 49.48M | Net income 2025 * | 8.3B 53.12M | EV / Sales 2024 | 1.58 x |
| Net Debt 2024 | 25.9B 166M | Net Debt 2025 * | 21.93B 140M | EV / Sales 2025 * | 1.4 x |
| P/E ratio 2024 |
12.2
x | P/E ratio 2025 * |
10.8
x | Employees | 1,729 |
| Yield 2024 |
2.06% | Yield 2025 * |
2.36% | Free-Float | 54.59% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.34% | ||
| 1 week | +5.42% | ||
| Current month | +2.87% | ||
| 1 month | -2.43% | ||
| 3 months | -3.54% | ||
| 6 months | +1.09% | ||
| Current year | +1.34% |
1 week
1 921.00
2 052.00
1 month
1 921.002 116.00
Current year
1 921.002 270.00
1 year
1 880.002 600.00
3 years
1 837.002 600.00
5 years
1 471.002 600.00
10 years
1 281.002 677.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sachiaki Ibe
CEO | Chief Executive Officer | 83 | 72-02-29 |
Mitsuhiro Ibe
PSD | President | 52 | 10-03-31 |
Yoshihiro Hiraga
CTO | Chief Tech/Sci/R&D Officer | 66 | 85-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sachiaki Ibe
CEO | Chief Executive Officer | 83 | 72-02-29 |
Tetsuo Komori
BRD | Director/Board Member | 76 | 06-05-31 |
Yoshihiro Hiraga
CTO | Chief Tech/Sci/R&D Officer | 66 | 85-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.21% | 19 M€ | +12.79% | ||
| 0.02% | 17 M€ | +16.94% | - | |
| 0.01% | 140,441 M€ | +17.38% | ||
| 0.01% | 63,295 M€ | +17.40% | - | |
| 0.01% | 20,360 M€ | +16.26% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 2,044 | +0.34% | 61 400 |
| 24-06-04 | 2,037 | +1.85% | 82,500 |
| 24-06-03 | 2,000 | +0.65% | 39,200 |
| 24-05-31 | 1,987 | +1.95% | 72,400 |
| 24-05-30 | 1,949 | +0.52% | 50,500 |
Delayed Quote Japan Exchange, June 05, 2024 at 02:00 am EDT
More quotes
Zeria Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the development of ethical drug business, consumer healthcare business and other business. The Company operates in two business segments. The Ethical Drug segment is engaged in the research, development, manufacture and sale of ethical drugs. The Consumer Healthcare segment is engaged in the manufacture, purchase and sale of over-the-counter (OTC) drugs, health foods, quasi drugs and cosmetics related to self-medication. The others include insurance agency business and real estate business, as well as various maintenance business such as purchasing and sale of promotional materials.
Sector
Pharmaceuticals
Calendar
2024-10-29
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2,037
JPY
Average target price
2,810
JPY
Spread / Average Target
+37.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.34% | 580M | |
| +17.87% | 41.07B | |
| +24.16% | 22.65B | |
| +20.24% | 14.14B | |
| +52.80% | 12.09B | |
| -0.05% | 6.79B | |
| -10.97% | 6.91B | |
| -8.87% | 5.73B | |
| +15.28% | 5.59B | |
| +4.00% | 4.82B |
- Stock Market
- Equities
- 4559 Stock
